SRR8518172
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.280
- ANGIOGENESIS+0.250
- HEDGEHOG_SIGNALING+0.250
- MYOGENESIS+0.240
- WNT_BETA_CATENIN_SIGNALING+0.230
- APICAL_JUNCTION+0.220
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.210
- UV_RESPONSE_DN+0.190
- HYPOXIA+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.640
- INTERFERON_GAMMA_RESPONSE-0.550
- ALLOGRAFT_REJECTION-0.380
- G2M_CHECKPOINT-0.340
- E2F_TARGETS-0.330
- IL6_JAK_STAT3_SIGNALING-0.320
- INFLAMMATORY_RESPONSE-0.260
- PI3K_AKT_MTOR_SIGNALING-0.260
- MITOTIC_SPINDLE-0.230
- MYC_TARGETS_V2-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-7421-01A-11R-2081-07 | — | — | 0.830 |
| 2 | TCGA-IQ-7631-01A-11R-2081-07 | — | — | 0.797 |
| 3 | TCGA-CV-6935-01A-11R-1915-07 | — | — | 0.791 |
| 4 | MBCProject_0504_T1_RNA | — | A | 0.786 |
| 5 | TCGA-AN-A0FS-01A-11R-A034-07 | — | A | 0.786 |
| 6 | TCGA-CV-7177-01A-11R-2016-07 | — | — | 0.785 |
| 7 | TCGA-AC-A3EH-01A-22R-A22K-07 | — | B | 0.775 |
| 8 | TCGA-CV-7103-01A-21R-2016-07 | — | — | 0.770 |
| 9 | BSR_08_0188_C3_S52 | — | A | 0.768 |
| 10 | TCGA-73-4675-01A-01R-1206-07 | — | cohortA2 | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.090 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.070 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |